Shots:

• The P-IV (PALADIN) study evaluates Iluvien (0.19mg) in 159 patients with DME prior received corticosteroid treatment without a significant rise in IOP for ~36mos. at 41 sites across the US
• In this study, patients treated with a single dose of Iluvien showed improvements in BCVA, CST & treatment burden @36mos., 70.5% reduction in treatment burden, 2.97% of eyes required IOP lowering surgery, 1.49% of patients received surgery due to steroid-related IOP elevation, IOP response predicted a similar outcome after Iluvien treatment
• In post hoc analysis, patients experienced higher visual acuity gains from baseline over patients who had >6 treatments before receiving Iluvien

 Ref: Globe Newswire | Image: Alimera